CriticalClass III antiarrhythmics (Vaughan Williams)×First-generation antihistamine with anxiolytic activity
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone is a class III antiarrhythmic that prolongs the QT interval, slows the heart rate and slows conduction. Its proarrhythmic effects are less frequent than with other antiarrhythmics and usually occur when other QT-prolonging factors are present, such as drug interactions or electrolyte disorders (amiodarone SmPC, AEMPS). The Spanish hydroxyzine SmPC names amiodarone among the drugs that raise the risk of arrhythmia when taken with hydroxyzine. It also asks for special caution with drugs that slow the heart rate (AEMPS). Amiodarone inhibits CYP3A4, and alcohol dehydrogenase and CYP3A4/5 metabolise hydroxyzine. The SmPCs expect higher hydroxyzine levels with strong inhibitors of these enzymes, but amiodarone is not among their examples (amiodarone and hydroxyzine SmPCs, AEMPS). Amiodarone has a half-life of 20–100 days, and its interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Amiodarone often slows the heart rate. Less often it causes conduction disorders (sinoatrial and atrioventricular block), new or worsened arrhythmias, sometimes with cardiac arrest, and torsade de pointes (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The adverse reactions of hydroxyzine include QT prolongation, ventricular arrhythmias such as torsade de pointes, and loss of consciousness (hydroxyzine SmPC, AEMPS). A slow pulse or an arrhythmia causes dizziness, palpitations and fainting.
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names amiodarone (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The amiodarone documents do not name hydroxyzine. Under the Spanish SmPC, combining amiodarone with QT-prolonging drugs requires a careful assessment of risks and benefits for each patient and QT monitoring. The SmPC also advises avoiding combinations with drugs that can cause arrhythmias (amiodarone SmPC, AEMPS). The US amiodarone label advises avoiding QT-prolonging drugs (amiodarone label, US Food and Drug Administration, FDA). The US hydroxyzine label recommends caution with amiodarone (hydroxyzine label, FDA), and the Spanish hydroxyzine SmPC is the strictest of all. Amiodarone interactions can persist for weeks to months after it is stopped (amiodarone SmPC, AEMPS, and FDA label). No document says how long to wait after amiodarone before starting hydroxyzine. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Before starting amiodarone, record an electrocardiogram (ECG), measure potassium and correct low potassium (amiodarone SmPC, AEMPS), and correct low magnesium and calcium as well (amiodarone FDA label). Stop amiodarone in second- or third-degree atrioventricular block, sinoatrial block or bifascicular block (amiodarone SmPC, AEMPS). If hydroxyzine and amiodarone have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage
- AEMPS: Ficha técnica: Hidroxizina (nº registro 80887), sección 4.5 (2025)– AEMPS, CIMA, nº registro 80887 (Hidroxizina Bluefish 25 mg comprimidos recubiertos con película EFG), revisión 04/2025 (texto revisado 10/2024), secciones 4.3, 4.4 y 4.5